NPCE — NeuroPace Inc

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1528287 ·
Last close
$15.16
Market Cap
$516.86M
52W High
$19.60
52W Low
$12.47
ADV30
190,070
Next earnings
2026-08-11
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 22,068,000 18,048,000 -5,568,000 -6,689,000 98,898,000 14,779,000 84,444,000
Dec 2025 26,588,000 20,578,000 -1,767,000 -2,729,000 105,565,000 21,692,000 86,534,000
Sep 2025 27,354,000 21,168,000 -2,600,000 -3,496,000 107,255,000 20,648,000 88,737,000
Jun 2025 23,520,000 18,132,000 -6,824,000 -8,651,000 106,114,000 22,857,000 86,676,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-9,424,000
Investing CF
$-412,000
Financing CF
$-1,674,000
CapEx
$-412,000
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-0.65
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-559,104,000
Inventory
$16,694,000
Receivables
$14,788,000
ST Investments
$39,202,000
EBIT TTM
$-14,740,000
Pretax Income TTM
$-21,565,000
Interest Exp TTM
$6,825,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$99,530,000
EBITDA
$-16,510,000
Free Cash Flow
$-2,739,000
Enterprise Value
$528,569,056
Total Cash
$53,981,000
Total Debt
$70,462,000
Shares Out
34,093,745
Trailing EPS
$-0.65
Book Value
$0.43
ROE
-111.4%
ROA
-10.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 99,986,000 -16,338,000 -21,465,000 105,565,000 86,534,000 -11,006,000
Dec 2024 79,906,000 -21,671,000 -27,141,000 94,647,000 86,634,000 -17,949,000
Dec 2023 65,421,000 -27,174,000 -32,956,000 107,651,000 86,997,000 -19,701,000
Dec 2022 45,520,000 -40,794,000 -47,082,000 114,106,000 79,329,000 -36,869,000

TTM Snapshot

Revenues TTM
$58,983,000
NetIncome TTM
$-32,577,000
OpCashFlow TTM
$0
Assets (Latest)
$94,647,000
Forward EPS
$-0.30

Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $10.00 · spot: $15.16 · call volume: 8 · put volume: 0

Peers — same industry

TickerNameMarket CapLastDaily %
CERS CERUS CORP $514.95M $2.57
CLPT ClearPoint Neuro, Inc. $504.12M $16.81
MDXG MIMEDX GROUP, INC. $537.69M $3.61
ANGO ANGIODYNAMICS INC $485.08M $11.74
MOBI Mobia Medical, Inc. $483.11M $14.53

News headlines (Yahoo Finance, 1h cache)

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade
2026-06-15 13:55 · Yahoo
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?
2026-06-11 15:30 · Yahoo
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
2026-06-10 14:38 · Yahoo
How The NeuroPace (NPCE) Investment Story Is Shifting Without A New Analyst Price Target
2026-06-02 22:07 · Yahoo
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
2026-05-29 12:05 · Yahoo
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
2026-05-29 12:00 · Yahoo
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?
2026-05-27 14:58 · Yahoo
NPCE Explains How NeuroPace's RNS System Makes Money
2026-05-27 14:45 · Yahoo
NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care
2026-05-27 14:34 · Yahoo
NeuroPace (NPCE) Q1 2026 Earnings Transcript
2026-05-14 19:23 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.